<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110107</url>
  </required_header>
  <id_info>
    <org_study_id>CA022-001</org_study_id>
    <secondary_id>2017-000597-11</secondary_id>
    <nct_id>NCT03110107</nct_id>
  </id_info>
  <brief_title>First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors</brief_title>
  <official_title>Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a Monoclonal Antibody both by itself and in
      combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 28, 2017</start_date>
  <completion_date type="Anticipated">March 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 6, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Safety and tolerability as measured by incidence of AEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Safety and tolerability as measured by incidence of SAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) of BMS-986218 monotherapy relative to Ipilimumab in immuno-oncology (IO) progressed melanoma cohort</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Assessment of preliminary efficacy and safety of BMS-986218 monotherapy relative to ipilimumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Duration of Response (mDOR) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Assessment of preliminary efficacy and safety of BMS-986218 monotherapy relative to ipilimumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Assessment of preliminary efficacy and safety of BMS-986218 monotherapy relative to ipilimumab</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR of BMS-986218 alone or in combination with Nivolumab</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Assessment of preliminary efficacy of BMS-986218 alone and in combination with nivolumab in advanced solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mDOR of BMS-986218 alone or in combination with Nivolumab</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Assessment of preliminary efficacy of BMS-986218 alone and in combination with nivolumab in advanced solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS of BMS-986218 alone or in combination with Nivolumab</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Assessment of preliminary efficacy of BMS-986218 alone and in combination with nivolumab in advanced solid tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibody (ADA) to BMS-986218</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of pharmacokinetics (PK) parameters and incidence of ADA to BMS-986218</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of change from baseline in T-regulatory cells (Tregs)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of Tregs and correlation/measure of association of anti-tumor activity and change (or % change) from baseline in Tregs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed serum concentration (Cmax)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed concentration (Tmax)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed serum concentration (Ctrough)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CLT)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average serum concentration over a dosing interval (AUC[TAU]/tau) at steady state (Css-avg)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of an exposure measure at steady state to that after the first dose [exposure measure includes AUC[TAU] and Cmax (AI)]</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal serum half-life if data permit (T-HALF)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentration at the end of a dosing interval (Ctau)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary measures of PK parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">452</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab Monotherapy and BMS-986218 Monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986218 in combination with Nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Monotherapy</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-986218</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Combination Therapy</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For more information regarding Bristol-Myers Squibb Clinical Trial participation,
             please visit www.BMSStudyConnect.com

          -  histologic or cytologic confirmation of a solid tumor that is advanced (metastatic,
             recurrent and/or unresectable)

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1

          -  Participants must have received, and then progressed, relapsed, or been intolerant to,
             all standard treatment regimens with proven survival benefit in the advanced or
             metastatic setting according to tumor type, if such a therapy exists

        Exclusion Criteria:

          -  Participants with primary CNS malignancies, or tumors with CNS metastases as the only
             site of disease, will be excluded

          -  Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior
             anti-cancer therapy and initiation of study therapy

          -  Prior anti-cancer treatments such as chemotherapy, radiotherapy, hormonal, or
             immunotherapy (including anti-PD-1/PD-L1) are permitted

        Other protocol defined inclusion/exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Gutierrez, Site 0002</last_name>
      <phone>551-996-5900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (Cumc)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Drake, Site 0001</last_name>
      <phone>646-317-3141</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Friedman, Site 0007</last_name>
      <phone>281-208-6570</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark O'Hara, Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0020</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0018</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0013</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

